BioCentury | Jun 30, 2020
Finance

Qiming-backed Gan & Lee hits ceiling to reach $5.2B market cap in first day on Shanghai

The latest in a string of Qiming portfolio companies to go public, Gan & Lee saw its stock gain the maximum allowed by the Shanghai exchange in its first day of trading to bring its...
BioCentury | Jun 12, 2020
Regulation

Approval of Biocon, Mylan insulin product could herald cheaper insulin in U.S.

After traveling a winding path that included patent disputes and complete response letters, Semglee insulin glargine from Biocon and Mylan has at last gained FDA’s approval to treat diabetes. Biocon Ltd. (NSE:BIOCON; BSE:532523) and Mylan...
BioCentury | Mar 11, 2020
Product Development

Biocon, Mylan look ahead to U.S. launch of insulin glargine as last Lantus patent falls for Sanofi

A district court decision in favor of Biocon and Mylan sets the partners up to launch their version of insulin glargine in the U.S. midyear should the candidate get FDA approval in June. The partners...
BC Extra | Jan 28, 2020
Company News

Jan. 27 Company Quick Takes: Enhertu meets in pivotal gastric cancer study; plus Biocon-Mylan, CMS, Lilly-Boehringer, Ningbo-Genentech

Japan submission on horizon for AZ, Daiichi’s ADC  Daiichi Sankyo Co. Ltd. (Tokyo:4568) plans to seek approval of Enhertu for gastric cancer starting in Japan after the anti-HER2 antibody-drug conjugate met the primary and a...
BC Extra | Oct 3, 2019
Politics & Policy

India, African countries will be first to benefit from Biocon’s cheaper insulin plan

Biocon will start making good on its promise of dime a day insulin for developing countries first in India and Africa, company founder Kiran Mazumdar-Shaw told BioCentury. Expanding the availability of low-cost insulin to other...
BC Extra | Sep 28, 2019
Politics & Policy

Biocon’s Mazumdar-Shaw pledges cheaper insulin for low income countries

Low and middle income countries would be able to purchase recombinant human insulin at a fraction of the current cost under a commitment by the founder of Indian biopharma Biocon, Kiran Mazumdar-Shaw. The current median...
BC Extra | Dec 11, 2018
Politics & Policy

FDA biosimilars policies will bring interchangeable insulin to market

New FDA policies will lead to approvals of interchangeable insulin products that can be automatically substituted for branded insulin, FDA Commissioner Scott Gottlieb said Tuesday. Gottlieb made the prediction in a statement about new guidance...
BC Week In Review | Sep 14, 2018
Company News

Sanofi creating China/emerging markets and primary care units

Sanofi (Euronext:SAN; NYSE:SNY) said it will create two new global business units early next year, one focused on China and emerging markets and the other on primary care. The China and emerging markets unit will...
BC Week In Review | Sep 13, 2018
Company News

Zealand brings in $205M for pipeline via royalty pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million....
BC Extra | Sep 13, 2018
Company News

Sanofi creating China/emerging markets and primary care units

Sanofi (Euronext:SAN; NYSE:SNY) said it will create two new global business units early next year, one focused on China and emerging markets and the other on primary care. The China and emerging markets unit will...
Items per page:
1 - 10 of 391